Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing.

ABSTRACT:

Background

Abuse liability assessments influence drug development, federal regulation, and clinical care. One suggested procedure to reduce variability of assessments is a qualification phase, which assesses whether study applicants adequately distinguish active drug from placebo; applicants failing to make this distinction are disqualified. The present analyses assessed differences between qualification phase qualifiers and non-qualifiers.

Methods

Data were collected from 23 completers of the qualification phase of an abuse liability study. Opioid abusing participants received 30 mg oxycodone and placebo orally on separate days, and were characterized as qualifiers (vs. non-qualifiers) if their peak visual analog scale liking rating for oxycodone was at least 20 points high

SUBMITTER: Antoine DG 

PROVIDER: S-EPMC3911782 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature